Left ventricular mass index and aortic arch calcification score are independent mortality predictors of maintenance hemodialysis patients

Hemodialysis International

Volumn 16, Issue 4, 2012, Pages 504-511

  Liu, Sha ^a   Zhang, Dong Liang ^a   Guo, Wang ^a   Cui, Wen Ying ^a   Liu, Wen Hu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Aortic arch calcification; Erythropoietin resistance index; Hemodiafiltration; Hemodialysis; Left ventricular mass index; Mortality

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FERRITIN; HEMOGLOBIN;

ADULT; AORTIC ARCH CALCIFICATION SCORE; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIAFILTRATION; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KAPLAN MEIER METHOD; LEFT VENTRICULAR MASS INDEX; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL TIME;

AORTA, THORACIC; AORTIC DISEASES; CALCIUM; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HEART VENTRICLES; HEMODIAFILTRATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS;

EID: 84867097024     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2012.00700.x     Document Type: Article

References (43)

1. Collins AJ, Kasiske B, Herzog C, etal. Excerpts from the United States renal data system 2004 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2005; 45:A5-A7, S1-280.
2. Stel VS, Kramer A, Zoccali C, etal. The 2006 ERA-EDTA registry annual report: A precis. J Nephrol. 2009; 22:1-12.
3. Rayner HC, Pisoni RL, Bommer J, etal. Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004; 19:108-120.
4. de Jager DJ, Grootendorst DC, Jager KJ, etal. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009; 302:1782-1789.
5. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-stage Renal Disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004.
6. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998; 9:S16-S23.
7. Longenecker JC, Coresh J, Powe NR, etal. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE study. J Am Soc Nephrol. 2002; 13:1918-1927.
8. Himmelfarb J, Stenvinkel P, Ikizler TA, etal. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62:1524-1538.
9. Vanholder R, Argiles A, Baurmeister U, etal. Uremic toxicity: present state of the art. Int J Artif Organs. 2001; 24:695-725.
10. Zimmermann J, Herrlinger S, Pruy A, etal. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55:648-658.
11. Vanholder R, Glorieux G, Lameire N. Uraemic toxins and cardiovascular disease. Nephrol Dial Transplant. 2003; 18:463-466.
12. deFilippi C, Wasserman S, Rosanio S, etal. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003; 290:353-359.
13. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005; 16 (Suppl 1):S83-S88.
14. Zoccali C, Benedetto FA, Mallamaci F, etal. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2001; 12:2768-2774.
15. Zoccali C, Benedetto FA, Tripepi G, etal. Left ventricular systolic function monitoring in asymptomatic dialysis patients: A prospective cohort study. J Am Soc Nephrol. 2006; 17:1460-1465.
16. Ogawa T, Ishida H, Matsuda N, etal. Simple evaluation of aortic arch calcification by chest radiography in hemodialysis patients. Hemodial Int. 2009; 13:301-306.
17. Ofsthun N, Labrecque J, Lacson E, etal. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003; 63:1908-1914.
18. Locatelli F, Pisoni RL, Combe C, etal. Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004; 19:121-132.
19. Levin A, Thompson CR, Ethier J, etal. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999; 34:125-134.
20. Schiffl H, Lang SM, Stratakis D, etal. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant. 2001; 16:1863-1869.
21. Panichi V, Rizza GM, Paoletti S, etal. Chronic inflammation and mortality in haemodialysis: Effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant. 2008; 23:2337-2343.
22. Kalantar-Zadeh K, Don BR, Rodriguez RA, etal. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2001; 37:564-572.
23. Hasuike Y, Nonoguchi H, Tokuyama M. Serum ferritin predicts prognosis in hemodialysis patients: The Nishinomiya study. Clin Exp Nephrol. 2010; 14:349-355. Epub 2010 May 14.
24. Ayus JC, Go AS, Valderrabano F, etal. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10g/dL. Kidney Int. 2005; 68:788-795.
25. Meeus F, Kourilsky O, Guerin AP, etal. Pathophysiology of cardiovascular disease in hemodialysis patients. Kidney Int Suppl. 2000; 76:S140-S147.
26. Vaziri ND, Dicus M, Ho ND, etal. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int. 2003; 63:179-185.
27. Zoccali C, Benedetto FA, Mallamaci F, etal. Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure. Eur J Clin Invest. 2003; 33:561-566.
28. Zoccali C, Mallamaci F, Maas R, etal. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002; 62:339-345.
29. Zoccali C, Benedetto FA, Mallamaci F, etal. Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004; 65:1492-1498.
30. Mitsutake R, Niimura H, Miura S, etal. Clinical significance of the coronary calcification score by multidetector row computed tomography for the evaluation of coronary stenosis in Japanese patients. Circ J. 2006; 70:1122-1127.
31. Moe SM, O'Neill KD, Duan D, etal. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002; 61:638-647.
32. Jono S, McKee MD, Murry CE, etal. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87:E10-E17.
33. Giachelli CM, Jono S, Shioi A, etal. Vascular calcification and inorganic phosphate. Am J Kidney Dis. 2001; 38:S34-S37.
34. Ketteler M, Bongartz P, Westenfeld R, etal. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet. 2003; 361:827-833.
35. Raggi P, Boulay A, Chasan-Taber S, etal. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease. J Am Coll Cardiol. 2002; 39:695-701.
36. Guerin AP, London GM, Marchais SJ, etal. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000; 15:1014-1021.
37. Kerr PB, Argiles A, Flavier JL, etal. Comparison of hemodialysis and hemodiafiltration: A long-term longitudinal study. Kidney Int. 1992; 41:1035-1040.
38. Canaud B, Wizemann V, Pizzarelli F, etal. Cellular interleukin-1 receptor antagonist production in patients receiving on-line haemodiafiltration therapy. Nephrol Dial Transplant. 2001; 16:2181-2187.
39. Bammens B, Evenepoel P, Verbeke K, etal. Removal of the protein-bound solute p-cresol by convective transport: A randomized crossover study. Am J Kidney Dis. 2004; 44:278-285.
40. Gerdemann A, Wagner Z, Solf A, etal. Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: Potential importance of dialysate quality. Nephrol Dial Transplant. 2002; 17:1045-1049.
41. Vaslaki L, Major L, Berta K, etal. On-line haemodiafiltration versus haemodialysis: Stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif. 2006; 24:163-173.
42. Velasco N. Convection with conviction-online hemodiafiltration for all: Single center clinical observations. Hemodial Int. 2006; 10 (Suppl 1):S67-S71.
43. Canaud B, Bragg-Gresham JL, Marshall MR, etal. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int. 2006; 69:2087-2093.